Don't know if many remember this PR from Mar of this year (see link below) but it provided great insight as to how far IPIX already had progressed in developing an oral form of Kevetrin thru pre-clinical studies and that the remaining safety studies should be completed by the end of this year so that a P1 in oral form can be started as soon as approved by FDA on healthy volunteers. The PR also shows the oral form is being well tolerated in rats up to 500mg/kg given orally for 7 days, the half-life is 1 hr and a statement that I took to mean a clearance rate equal to that found in intravenous Kevetrin testing. So Kevetrin has not been put on a shelf this year while OC trial ongoing.

Anyone have any idea how long a P1 on healthy candidates should take when only criteria seems to be how well trial members tolerate the oral form of K and the safety of oral K in regards to these studies: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports?

Have no idea how this work on oral K could be used for oral P but I am sure company is learning a lot which should benefit us all down the line in bringing about an oral P as soon as possible.

http://www.ipharminc.com/press-release/2017/3...ncer-agent